Solid Biosciences is ​a ​biotech ​company focused on​ ​Duchenne ​muscular ​dystrophy

Latest news

Latest news

Solid GT Raises $42.5 Million in Series B Financing

Cambridge, MA
November 3, 2015

The round was led by Biogen and Perceptive Advisors, to advance the development of its gene therapy platform for Duchenne muscular dystrophy.
Press release
Xconomy article

We announce drug development partnership with Debiopharm

Lausanne, Switzerland, and Cambridge, USA
September 8, 2015

Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular dystrophy.
Read more

SOLIDPURPOSE

SOLID PURPOSE

Solid exists to advance treatments and find a cure for patients with Duchenne muscular dystrophy.

Hard facts

Duchenne muscular dystrophy is considered a rare disease yet there are an estimated 300,000 sufferers worldwide. DMD has devastating impact. DMD is the most common genetic killer in children, overwhelmingly affecting boys. The rate of occurrence is estimated at one in every 3,600 boys born and has no ethnic, geographic, racial or religious boundary. Diagnosis usually comes between ages 3 and 5 due to pronounced muscle weakness. Unable to live normal lives, patients are wheelchair-bound by early teens, typically succumbing to respiratory or heart failure in their 20s. DMD is 100% fatal.

Therapeutic gap

There is no cure for DMD and no approved treatments on the market. It's bleak for patients and their families and costly for the wider community. As DMD is a rare disease, treatments tend to languish on lab shelves for lack of funding and perceived financial opportunity. It's frustrating for scientists and a struggle for families with children with DMD.

Solid’s 1 in 3600

In 2012 a little boy named Eytani – which means Solid in Hebrew – was diagnosed with DMD. His father Ilan Ganot was devastated by the news and vowed to find treatments. Ilan left his career in finance, relocated with his family from London to Massachusetts, put a team in place, raised seed capital and founded Solid. Like other parent-driven efforts, Ilan's passion, focus and unrelenting motivation are the driving force behind Solid.

 

Some of the world’s most brilliant scientists
are developing therapies ripe for DMD

BRIGHT HORIZON

There is a shift in the development landscape, with several treatments in clinical trials and many more therapies in the pipeline. With a focused direction and the right momentum, these programs can benefit many young lives.
 

THE SOLID ADVANTAGE

Solid exists to bridge the gap and advance treatments to patients. Well-capitalized and focused on results, we are purpose-built to identify and develop the most promising approaches to treat and cure DMD. To further that goal, Solid has a strong management team with access to an unparalleled network of scientific, clinical, strategic and regulatory experts.

 

 

 

 

 

 

solid promise

SOLID PROMISE
 

SIDE BY SIDE

Condition-Focused. Patient-Focused.

 

A Biotech company built solely for DMD, we bring sharp
commercial focus and world-class science to advance
promising therapies.

Solid is a catalyst across all aspects of the disease.
Condition-focused, our mandate is comprehensive;
improving daily life for patients and attacking the roots of DMD.

 

OUR APPROACH

IMPACTFUL

Carving a new path for patients with Duchenne muscular dystrophy.

FOCUSED

World-class scientific expertise and strong financial backing allows us to curate excellent programs. Investment dollars are wisely deployed.

AGILE

Independent and lean, we avoid bureaucracy and dead ends.  

FAST

We propel projects from laboratory to pharmacy shelf, with a guiding hand to ensure best  execution.  

ACCOUNTABLE

High degree of control. Results driven culture. We cut out middlemen and reduce risk in addressing DMD.  

PASSIONATE

Our heart is in it. Patients can’t wait, nor will we. If a program shows promise, we propel forward;  if it doesn’t, we quickly move on to the next.  

solid leadership

SOLID COMPANY

Board of directors

Ilan Ganot

Ilan Ganot

CEO, Founder and Board Member View Bio
Andrey Zarur,  Ph.D.

Andrey Zarur, Ph.D.

Founder and Chairman of the board View Bio
Gilad Hayeem

Gilad Hayeem

Founder and Board Member View Bio
Matt Arnold

Matt Arnold

BOARD MEMBER View Bio
Robbie L. Huffines

Robbie L. Huffines

Board Member View Bio
Ilan Ganot

Ilan Ganot

CEO, Founder and Board Member

Mr. Ganot is Founder, CEO of Solid Biosciences and Solid GT and member of the board of directors of both companies. Prior to starting Solid, Mr. Ganot was an investment banker at JPMorgan Chase in London, specializing in hedge funds driven equities business for the firm. Mr. Ganot also worked at Nomura Securities in London, Hong Kong and New York and Lehman Brothers in Europe.

Mr. Ganot embarked on a banking career after practicing law at Israeli law-firm, Haim Zadok & Co, where his focus was private equity law and mergers and acquisitions. Mr. Ganot was a captain in the Israel Defense Forces. Mr. Ganot received his MBA from London Business school and holds law and business degrees from the IDC in Herzliya, Israel.

Andrey Zarur,  Ph.D.

Andrey Zarur, Ph.D.

Founder and Chairman of the board

Dr. Zarur is Founder and Chairman of the board for Solid. He has been active in early stage life sciences companies for over 20 years, and has actively participated in the creation of over a dozen companies in the healthcare and clean energy sectors. He is also Chairman, CEO and Founder of GreenLight Biosciences and a partner at Kodiak Venture Partners, a venture capital firm specializing in the formation of early stage information and life technology investments. Prior to joining Kodiak Venture Partners, he was founder and CEO of BioProcessors (sold to Seahorse Biosciences in 2007). In addition to BioProcessors, he has led four life science companies from inception to exit. He is also a co-founder and chairman of the board for Lumicell, and chairman of the board for Allegro Diagnostics.

Dr. Zarur was named a Young Global Leader of the World Economic Forum in 2005, and he is an Overseer of the Museum of Science in Boston and a Senior Lecturer at MIT Sloan School of Management. Dr. Zarur holds Masters of Science degrees and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, and undergraduate degrees from the National University of Mexico. Dr. Zarur is the author of several peer-reviewed articles and holds close to 100 provisional and issued patents.

Gilad Hayeem

Gilad Hayeem

Founder and Board Member

Gilad Hayeem founded Solid Biosciences through his Family Office, Waverly Capital, and led the Series A round alongside JPMorgan. He is a member of the boards of Solid Biosciences and Solid GT and an active manager.

Mr. Hayeem was Managing Partner and CEO of Marble Bar Asset Management, a UK based investment fund he founded in 2002 and sold in 2008. Mr. Hayeem then moved to New York where he lives with his wife and four children.

Mr. Hayeem received his MBA from City University, London, and holds history and politics degrees from the University of Leeds, England.

Matt Arnold

Matt Arnold

BOARD MEMBER

Mr. Arnold is member of the board of directors for Solid. His background is in energy commodities and he was Managing Director of Constellation Energy Global Commodities in London from 2005 – 2009 when it was sold to Goldman Sachs. Prior to joining Constellation in 2002, Mr. Arnold worked in energy trading and finance at Enron. Since 2009, Mr. Arnold has been actively working with startup businesses in the UK and Europe, primarily in the technology and clean tech sectors. He holds an MS in Environmental Engineering from the University of Virginia and an undergraduate degree from Duke University.

Robbie L. Huffines

Robbie L. Huffines

Board Member

Mr. Huffines joined J.P. Morgan in 1991 and is currently a Vice Chairman of Investment Banking. Starting in the Mergers and Acquisitions group – where he was healthcare focused – Mr. Huffines was Co-Head of the Global Healthcare Investment Banking Group from 2002 – 2010, promoted to Vice Chairman in 2011.

Mr. Huffines has advised numerous healthcare companies on strategic transactions including J&J’s sale of Ortho Clinical Diagnostics (pending); Thermo Fisher’s acquisition of Life Technologies, Kinetic Concepts go-private; Sanofi-Aventis on its acquisition of Genzyme; Merck’s acquisition of Schering Plough; Guidant’s sale to Boston Scientific and Abbott; Bristol-Myers Squibb’s acquisition of Medarex; Celgene’s acquisition of Pharmion; Kinetic Concept’s acquisition of LifeCell, Amgen’s acquisition of Mustafa Nevzat and sale of Amgen K.K. to Takeda; Eisai’s acquisition of MGI Pharmaceuticals; Merck’s acquisition of Banyu Pharmaceuticals and divestiture of Medco Health Solutions; Bristol-Myers Squibb’s divestitures of Medical Imaging, Zimmer, and Mead Johnson and acquisition of Dupont Pharmaceuticals; Guidant’s acquisition of CardioThoracic Systems and Cook (withdrawn); Sofamor Danek’s sale to Medtronic; and Johnson & Johnson’s acquisitions of Mitek, Cordis, and Neutrogena and sale of Janssen Annual Health.

At J.P. Morgan, Mr. Huffines has extensive experience financing healthcare companies. Prior to joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons, specializing in equity financings and advisory assignments for emerging growth companies. Mr. Huffines has an MBA degree from the University of Virginia, where he received the Faculty Award for academic excellence. He has a B.A. degree from the University of North Carolina, where he majored in English and Economics. Mr. Huffines is married and has four children.

His volunteer work includes The Brookings/Gates Global Health Innovative Financing Advisory Group, the Student Sponsor Partnership, a member of the Corporate Advisory Board at the Darden School, and serving as a Board Member of the Spence School and Solid Biosciences.

Team

Team

Jorge A. Quiroz MD, MBA

Jorge A. Quiroz MD, MBA

Chief Medical Officer View Bio
Alvaro Amorrortu

Alvaro Amorrortu

SVP OPERATIONS View Bio
Carl Morris Ph.D.

Carl Morris Ph.D.

VP, Research & Development View Bio
Joel Schneider Ph.D.

Joel Schneider Ph.D.

Director, Research & Development View Bio
Charles Legg

Charles Legg

Solid GT Head of Program Management View Bio
Carlene Barous

Carlene Barous

SENIOR REGULATORY MANAGER View Bio
Michael Struharik

Michael Struharik

Solid GT Preclinical Coordinator View Bio
Annie Ganot

Annie Ganot

Patient Advocacy View Bio
Kathryn Wagner, MD, Ph.D.

Kathryn Wagner, MD, Ph.D.

EXECUTIVE MEDICAL LEAD View Bio
Robert Lu Ph.D.

Robert Lu Ph.D.

Solid GT Associate Director of Manufacturing & Process Development View Bio
Gaelyn Flannery

Gaelyn Flannery

Solid GT Quality Assurance Manager View Bio
Tayjus Surampudi

Tayjus Surampudi

Project coordinator View Bio
Karin Folman

Karin Folman

Branding and Design View Bio
Valorie Kopp-Aharonov

Valorie Kopp-Aharonov

Executive Assistant View Bio
Kerry Rosenfeld

Kerry Rosenfeld

Patient Advocacy View Bio
Christianne Baruqui

Christianne Baruqui

HUMAN RESOURCES View Bio
Jorge A. Quiroz MD, MBA

Jorge A. Quiroz MD, MBA

Chief Medical Officer

Prior to Joining Solid GT, Dr. Quiroz served as the Head of Neurodevelopment & Psychiatry, Translational Medicine Neurosciences at Hoffmann-La Roche. A medical graduate from the Pontifical Catholic University of Chile and Board Certified Psychiatrist, he completed his medical training as a Research Fellow at the Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, at the National Institutes of Health in Bethesda, Maryland. He also holds a Master of Business Administration dual degree from Columbia University & London Business School.

Dr. Quiroz received the NARSAD Young Investigator Award, the NCDEU New Investigator Award, the Fellows Award for Research Excellence, and the NIH Clinical Center Director’s Award, among other distinctions. He has designed and conducted numerous proof of concept studies, including studies in orphan designated indications, and has successfully filed New Drug Applications with the FDA during his tenure at Johnson & Johnson Pharmaceutical Research and Development and Hoffmann-La Roche. Dr. Quiroz has published over 45 peer reviewed scientific publications and book chapters in the fields of translational neurosciences and drug development.

He also completed studies as a professional violinist at the National Conservatory in the University of Chile.

Alvaro Amorrortu

Alvaro Amorrortu

SVP OPERATIONS

Mr. Amorrortu is Senior Vice President of Operations of Solid Biosciences, responsible for building and supporting the infrastructure to enable execution of Solid’s programs.

Prior to joining Solid Biosciences, Mr. Amorrortu spent more than a decade as a management consultant advising biopharmaceutical companies on a variety of strategic challenges, including overseeing large scale organizational transformations as well as designing strategies for assets and portfolios moving from early stages of development to commercial launch. His career as a strategist started at the Monitor Group, and then after a few years working for Inventiv Health (Campbell Alliance), moved to IMS Health.
In addition, Mr. Amorrortu brings to Solid Bio, hands on experience managing operations. He held leadership positions in Bunge Group and Cargill subsidiaries, where he was responsible for running manufacturing facilities as well as complex engineering projects.

Mr. Amorrortu received his M.B.A. with a major in Finance from The Wharton School and graduated from the Instituto Tecnologico de Buenos Aires, Argentina with an MS in Industrial Engineering. An avid traveler, he has lived and worked in Argentina, Paraguay, Spain, Switzerland and the United States.

Carl Morris Ph.D.

Carl Morris Ph.D.

VP, Research & Development

Dr. Morris is the VP of Research and Development, responsible for overseeing the drug
development processes for Solid Biosciences. Prior to joining Solid, Dr. Morris was a Senior
Director for Pfizer’s Rare Disease Research Unit, leading their efforts in neurologic diseases and the muscle biology programs. While at Pfizer, Dr. Morris directed several small molecule and biotherapeutic development programs, including a program that led to a Phase 2 study in Duchenne Muscular Dystrophy, while also heading an internal research group responsible for advancing programs from target identification to the clinic for many of the rare neurologic and muscle-related diseases. Dr. Morris identified key external opportunities and worked closely with patient groups, academic laboratories, and other industry partners to advance drug development in the rare neuromuscular space. His scientific and drug development experience at Pfizer also included investigations into broader muscle wasting conditions, as well as tendon and bone repair biology.

Prior to joining Pfizer in 2007, Dr. Morris was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit, established to investigate strategies for improving muscle function during aging or disease. He completed his Postdoctoral fellowship in the Department of Physiology at the University of Pennsylvania where he worked on multiple projects ranging from molecular aspects of muscle protein interactions through to therapeutic approaches for modulating muscle size and function. As a trained muscle physiologist, his academic pursuits have ranged from biophysical aspects of muscle contraction and enzyme kinetics to therapeutic interventions in a variety of in vivo muscle atrophy and disease models.

Dr. Morris holds a B.A. in Biology from Franklin Pierce College (Rindge, NH) and a PhD in
Physiology from UCLA.

Joel Schneider Ph.D.

Joel Schneider Ph.D.

Director, Research & Development

Dr. Schneider is the Director of Research & Development for Solid, responsible for the identification and development of promising therapies for DMD. Dr. Schneider previously completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology, characterizing and developing small molecules that enhance skeletal muscle regeneration. He holds a Ph.D. from Rutgers University and an undergraduate degree from Brandeis University. During his doctoral work, Dr. Schneider studied the cardiomyopathy associated with Duchenne muscular dystrophy and is the author of numerous peer-reviewed articles related to Duchenne muscular dystrophy and stem cell biology.

Charles Legg

Charles Legg

Solid GT Head of Program Management

Mr. Legg is an experienced leader in the development and commercialization of severe, orphan class diseases. Prior to joining Solid GT, he was the Director of Program Management at bluebird bio where he was responsible for leading the efforts to achieve their first 3 INDs and subsequent clinical development of lentiviral gene therapy approaches for ALD, Beta-Thalassemia and Sickle Cell Anemia. Before bluebird, Mr. Legg spent 8 plus years at Shire in their program management group managing the development and commercialization of enzyme replacement therapies for multiple rare disease programs. Before developing human therapies, Mr. Legg was responsible for managing the development of regulated and quality compliant diagnostics and software driven diagnostic platforms for the healthcare industry along with several years working in the lab on protein and peptide cloning, expression, scale-up, characterization and managing joint scientific collaborations.
Mr. Legg has a degree in Biology with a concentration in Cell & Molecular Biology/Biochemistry from Colby College in Waterville, ME.

Carlene Barous

Carlene Barous

SENIOR REGULATORY MANAGER

Carlene Barous is Solid GT’s Senior Regulatory Manager. In this role, Ms. Barous is formulating the regulatory strategy and driving the tactical execution of regulatory submissions to the FDA and other national health agencies for the Solid GT program.

Ms. Barous has worked in the biotechnology industry since 1996 in support of regulatory compliance, change control, and submissions management for marketed and development biologic products. Ms. Barous most recently worked at Shire as a regulatory manager where she was responsible for leading global regulatory affairs into a new GMP change control system. Before Shire, Carlene spent over two years as an embedded regulatory liaison at a Genzyme manufacturing facility where she was responsible for providing real time change control assessment and strategy advice. Ms. Barous started her biotech career at Biogen where she held various positions over nearly 14 years involving regulatory submission management and writing, license maintenance, change control coordination, and international product registration support.

Ms. Barous obtained a BA degree in Political Science from Boston College in 1987 and is currently a BS degree candidate in Biomedical Laboratory and Clinical Sciences at Boston University. Ms. Barous has been certified by the Regulatory Affairs Professional Society in US Regulatory Affairs since 2007.

Michael Struharik

Michael Struharik

Solid GT Preclinical Coordinator

Mr. Struharik’s role in supporting all preclinical work at Solid GT is founded upon his experience with Rx-Gen, Inc., a contract research organization spinout from Yale School of Medicine. He has significant experience in the establishment of research platforms and validation of disease models. Of particular interest for DMD, he also has experience in the development of a medical imaging platform in 3D gait analysis which generated data to support a successful IND application. Mr. Struharik was also an integral part of establishing the quality systems for GLP compliance and AAALAC accreditation at Rx-Gen. Prior to his laboratory experience, he was a high school science teacher. Mr. Struharik holds a degree in Biology with focus on Evolutionary Biology and Neuroscience from The Ohio State University.

Annie Ganot

Annie Ganot

Patient Advocacy

Ms. Ganot is a Founder and co-leads Solid’s Patient Advocacy group, responsible for the Americas.

Ms. Ganot was Head of Corporate Events at Lehman Brothers investment bank in London. Prior to Lehman Brothers, Ms. Ganot worked in communications and events at Morgan Stanley and Deutsche Bank in New York and London. Ms. Ganot has a degree in Communications from the University of Wisconsin – Madison and is mother of a five year old son with Duchenne muscular dystrophy.

Kathryn Wagner, MD, Ph.D.

Kathryn Wagner, MD, Ph.D.

EXECUTIVE MEDICAL LEAD

Director, Center for Genetic Muscle Disorders
Kennedy Krieger Institute
Associate prof. of neurology & neuroscience
Johns Hopkins School of Medicine.
Dr. Wagner obtained her undergraduate degree from Yale University, graduating summa cum laude with honors in biology. She participated in the NIH-funded medical scientist training program and obtained her medical and doctoral degrees at Johns Hopkins. Her thesis work in the laboratory of Richard Huganir, Ph.D., included the original cloning and characterization of the dystrophin-associated protein, dystrobrevin.
She completed her internship in internal medicine and residency in neurology at Johns Hopkins. She went on to complete a neuromuscular fellowship at Hopkins and a clinical neurogenetics fellowship with Kenneth Fischbeck, M.D., at the National Institutes of Health. With Dr. Fischbeck, she conducted the first clinical trial attempting to suppress nonsense mutations in Duchenne muscular dystrophy patients. In 2000, Dr. Wagner joined the faculty at Johns Hopkins, and in June 2009, joined the Kennedy Krieger Institute to allow her patients with muscular dystrophy to benefit from the institute’s historical strengths in rehabilitation and neurogenetics.

Robert Lu Ph.D.

Robert Lu Ph.D.

Solid GT Associate Director of Manufacturing & Process Development

Dr. Lu is the Associate Director of Process Development and Manufacturing at Solid
GT.

Dr. Lu has ten years of experience in the therapeutic protein process development
and manufacturing. He joined Solid GT from Genzyme where he was Manager in the
Manufacturing Science and Technology department, and spent the last three years
managing a team of engineers for the upstream development/optimization to support
Cerezyme manufacturing, and worked closely with downstream purification and all of
the analytical characterization.

Prior to Genzyme, Dr. Lu also had experience working for Percivia – a smaller biotech company focused on the PER.C6 cell platform development, and at Shire working on several of their rare disease programs involving enzyme replacement therapies and the process development supporting. Dr. Lu received his Bachelor’s from Peking University (China) and his PhD from Brown University (Rhode Island).

Gaelyn Flannery

Gaelyn Flannery

Solid GT Quality Assurance Manager

Gaelyn Flannery is Quality Assurance Manager for Solid GT. Ms. Flannery began her career in the biotech industry at the age of nineteen. After completion of a Biotech certificate program at Boston University, Ms. Flannery was hired as an assistant technician in a Quality Control lab. After working in a Quality laboratory for several years, she transitioned into a Quality Assurance role supporting the daily manufacturing activities ensuring compliance to regulatory standards. Ms. Flannery has worked over fourteen years in two of the area’s largest Biotechnology companies in a wide range of Quality Assurance functions. Most recently she held the role of Quality Assurance Manager at a smaller, clinical phase company where her background and experience in the Quality arena helped her transition into a function establishing Quality Management Systems. Her several years of supporting the manufacture of therapies in the rare disease community illustrate her commitment to ensuring we here at Solid deliver a safe and efficacious therapy to the DMD community, which at this time is an unmet need.

Ms. Flannery is currently in the process of completing a degree in the life sciences at Southern New Hampshire University to help further her personal and professional goals, while demonstrating her commitment to our patient community.

Tayjus Surampudi

Tayjus Surampudi

Project coordinator

Mr. Surampudi joins Solid GT under contract as a Project Coordinator to interface with patient communities and help with various projects, including governmental affairs and assessment of new legislation and regulatory guidances important to the community and the effort to address DMD.

Mr. Surampudi, who has DMD himself, has been deeply involved in patient advocacy with experience that includes a seat on the patient advisory committee for the Parent Project for Muscular Dystrophy (PPMD), as well as a previous internship at PTC that was focused on patient advocacy and marketing.

Mr. Surampudi is student at Harvard University, where he is studying Government.

Karin Folman

Karin Folman

Branding and Design

A highly trained creative, Ms. Folman brings pinpoint focus to business needs. Clients greatly benefit from her combined approach, which integrates business with design, every step of the way.

A BFA in Graphic Design from New York’s School of Visual Arts led to design agencies Slover & Co. and Neo Group. With a desire to learn the commercial aspects of design, Ms Folman studied a Masters in Design Management at Bezalel Academy.

Over twelve years experience, Ms. Folman created brands for retail, hospitality, high-tech, pharma, real estate, cosmetics and FMCG.

Valorie Kopp-Aharonov

Valorie Kopp-Aharonov

Executive Assistant

Ms. Kopp-Aharanov is the Executive Assistant at Solid Biosciences. She has filled senior administrative positions in hi-tech companies in Israel and comes to Solid from Harvard Medical School where she served as the Executive Assistant to the Chair of the Neurobiology Department. Val holds an MS in Communication Disorders from the University of Oklahoma Medical Center and an undergraduate degree from Washington University-St. Louis.

Kerry Rosenfeld

Kerry Rosenfeld

Patient Advocacy

Ms. Rosenfeld co-leads Solid’s Patient Advocacy group, responsible for Europe & Asia.

Ms. Rosenfeld worked for several years at United Bank of Switzerland, and then as a commercial property consultant and business development consultant part time for several companies while raising her four young children. In 2007 Ms. Rosenfeld co- founded the UK charity Duchenne Research Fund with the aim of funding research to find a cure for Duchenne, and she continues to lead the charity’s activities part time. She is mother to a thirteen year old son with Duchenne.

Christianne Baruqui

Christianne Baruqui

HUMAN RESOURCES

Ms. Baruqui is the Human Resources consultant for Solid Biosciences. She is Head of HR at Greenlight Biosciences , taking care of all HR issues. Enthusiastic HR Professional with great professional experience, passion for HR and advanced education in Human Resources. A co-founder of BioProcessors, Ms. Baruqui has significant experience in Human Resources Management and international banking. After tenure at Citibank as credit manager, internal auditor and controller, she joined Starlab in Belgium, where she was in charge of recruitment and management for a plant of over a hundred international scientists. She studied Business Administration and Human Resources Management at Lesley University in Cambridge and also holds a Master’s Degree in Business and HR from Suffolk University.

SOLID media

SOLID MEDIA

  • Company Name
  • Company Name
  • Company Name
  • Company Name
  • Company Name
  • Company Name
  • Company Name
  • Company Name

 

 

contact

SOLID LOCATION
 

FRONT SEAT

Access to Excellence

 

Solid is headquartered in Cambridge, Massachusetts, biotech capital of the world.
With offices at Kendall Square, Solid benefits from superb access to scientists,
academia, pharmaceutical companies, hospitals and many like-minded companies
and individuals.

CONTACT US

One Broadway, Cambridge MA 02142 (map)

 info@solidbio.com
 jobs@solidbio.com

 Sponsored Research Policy

To receive latest news from Solid please provide your details